Spyre Therapeutics Inc (NASDAQ: SYRE) is 3.18% higher on its value in year-to-date trading and has touched a low of $20.07 and a high of $47.97 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The SYRE stock was last observed hovering at around $24.35 in the last trading session, with the day’s loss setting it -0.33%.
Currently trading at $24.02, the stock is -0.39% and -15.27% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.48 million and changing -1.36% at the moment leaves the stock -20.67% off its SMA200. SYRE registered -3.53% loss for a year compared to 6-month loss of -13.85%. The firm has a 50-day simple moving average (SMA 50) of $28.5659 and a 200-day simple moving average (SMA200) of $30.36615.
The stock witnessed a -11.30% gain in the last 1 month and extending the period to 3 months gives it a -13.85%, and is 3.18% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.16% over the week and 6.16% over the month.
Spyre Therapeutics Inc (SYRE) has around 30 employees, a market worth around $1.41B and $0.00M in sales. Current P/E ratio is 2.61. Distance from 52-week low is 19.68% and -49.93% from its 52-week high. The company has generated returns on investments over the last 12 months (22.56%).
The EPS is expected to grow by 91.27% this year
The shares outstanding are 51.40M, and float is at 50.01M with Short Float at 19.24%.
The top institutional shareholder in the company is FMR LLC with over 7.51 million shares valued at $176.51 million. The investor’s holdings represent 16.568 of the SYRE Shares outstanding. As of 2024-06-30, the second largest holder is FAIRMOUNT FUNDS MANAGEMENT LLC with 4.02 million shares valued at $94.47 million to account for 8.8668 of the shares outstanding. The other top investors are RTW INVESTMENTS, LP which holds 3.26 million shares representing 7.1903 and valued at over $76.6 million, while PERCEPTIVE ADVISORS LLC holds 6.6886 of the shares totaling 3.03 million with a market value of $71.26 million.
Spyre Therapeutics Inc (SYRE) Insider Activity
The most recent transaction is an insider sale by Albers Jeffrey W., the company’s Director. SEC filings show that Albers Jeffrey W. sold 6,700 shares of the company’s common stock on Nov 06 ’24 at a price of $36.76 per share for a total of $0.25 million. Following the sale, the insider now owns 27360.0 shares.
Spyre Therapeutics Inc disclosed in a document filed with the SEC on Oct 25 ’24 that Albers Jeffrey W. (Director) sold a total of 300 shares of the company’s common stock. The trade occurred on Oct 25 ’24 and was made at $36.43 per share for $10929.0. Following the transaction, the insider now directly holds 34060.0 shares of the SYRE stock.
Still, SEC filings show that on Oct 25 ’24, SESSIONS, LLC (Director) Proposed Sale 7,000 shares at an average price of $33.70 for $0.24 million. The insider now directly holds shares of Spyre Therapeutics Inc (SYRE).
